NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,481.75 -96.55 (-0.52%) CRUDE OIL
78.59 +0.11 (+0.14%) GOLD FUTURES
2,327.20 -4.00 (-0.17%) DOW
38,852.27 +176.59 (+0.46%) Bitcoin GBP
50,637.78 -643.73 (-1.26%)
AstraZeneca PLC (AZN.ST)
| Previous close | 1,634.00 |
| Open | 1,634.00 |
| Bid | 1,633.00 x 0 |
| Ask | 1,633.50 x 0 |
| Day's range | 1,624.50 - 1,645.50 |
| 52-week range | 1,261.00 - 1,695.00 |
| Volume | |
| Avg. volume | 336,380 |
| Market cap | 2.536T |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 37.31 |
| EPS (TTM) | 43.79 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | 30.74 (1.88%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | 1,289.07 |
ZacksWhy Astrazeneca (AZN) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
ZacksThe Zacks Analyst Blog Highlights AstraZeneca, Qualcomm, FedEx, American International and Baker Hughes
AstraZeneca, Qualcomm, FedEx, American International and Baker Hughes are included in this Analyst Blog.
GlobeNewswireCellectis Announces Completion of the Additional Equity Investment by AstraZeneca
Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that, following clearance from the French Ministry of Economy and satisfaction of all other closing conditions, AstraZeneca (LSE/STO/Nasda
